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Objectives This study sought to describe the natural history of combined stenotic and regurgitant aortic valve disease.
Background Data on outcome and prognostic factors in combined aortic valve disease are scarce.
Methods This study prospectively followed 71 consecutive asymptomatic patients (21 women, age 52  17 years) with at
least moderate aortic stenosis in combination with at least moderate aortic regurgitation and preserved left ven-
tricular function (ejection fraction 55%).
Results During a median potential follow-up of 8.9 years, 50 patients developed an indication for aortic valve replace-
ment and no cardiac deaths were observed. Overall event rates were high with an event-free survival for the en-
tire patient population of 82  5%, 62  6%, 49  6%, 33  6%, and 19  5% at 1, 2, 3, 4, and 6 years, re-
spectively. There was 1 operative and no post-operative deaths. Peak aortic jet velocity (AV-Vel) independently
predicted event-free survival. Patients with an AV-Vel between 3 and 3.9 m/s had an event-free survival of
94  4%, 88  6%, 65  9%, and 51  9% after 1, 2, 4, and 6 years, respectively, compared with 92  4%,
67  7%, 38  8%, and 12  6% for patients with an AV-Vel between 4 and 4.9 m/s and 67  8%, 39  10%,
17  9%, and 0% for patients with an AV-Vel 5 m/s (p  0.0001).
Conclusions Asymptomatic patients with combined aortic valve disease can be safely followed until surgical criteria defined
for aortic stenosis, aortic regurgitation, or the aorta are reached. However, high event rates can be expected
even in younger patients and those with only moderate disease. AV-Vel, which reflects both stenosis and regurgi-
tant severity, provides an objective and easily assessable predictive parameter. (J Am Coll Cardiol 2013;61:
1489–95) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.070Aortic valve disease is frequently encountered in clinical
practice with a prevalence of 2% in patients between 65 and
75 years and of 6% in patients older than 75 years in
population-based studies (1). Aortic stenosis (AS) is the
most common single-valve disease accounting for one-third
See page 1496
of patients referred to treatment, followed by aortic regur-
gitation (AR), which accounts for 10% of those referred to
surgery (2). Data on combined stenotic and regurgitant
aortic valve disease are scarce, both with regard to its
epidemiological prevalence and even more importantly with
regard to its natural history (3). Knowledge of this infor-
mation would be needed for an adequate clinical decision-
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20, 2012, accepted November 27, 2012.making process (4). The management guidelines conclude
that data on mixed valve disease are lacking and thus
making evidence-based recommendations is difficult
(5,6). In clinical practice, management of patients with
combined aortic disease follows the recommendations
concerning the predominant lesion and in the case of
balanced stenosis and regurgitation on how well the
lesion is tolerated by the patient (5). However, the
combination of pressure and volume load represents a
distinct form of myocardial stress. Symptoms warrant
surgery, both in AS and in AR (7,8). Furthermore,
surgery is indicated in asymptomatic patients with AS or
AR when left ventricular function is impaired (5,9,10). In
AR, marked left ventricular dilation is also considered as
an indication for surgery (9,11). Early elective surgery
may be considered in asymptomatic AS patients with
rapid hemodynamic progression (increase in peak aortic
jet velocity [AV-Vel] of at least 0.3 m/s/year) in the
presence of a calcified aortic valve (5,6,12).
Whereas no predictors of outcome have been defined for
combined aortic valve disease, AV-Vel is of interest in this
regard because it is affected by the severity of both AS and
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parameter reflecting the overall
hemodynamic load on the left
ventricle. AV-Vel has been pre-
viously identified as an important
predictor of outcome in asymp-
tomatic patients with AS with-
out coexisting AR (12–15).
Therefore, we prospectively stud-
ied a cohort of consecutive asymptomatic patients with combined
aortic valve disease having at least moderate stenosis and moderate
regurgitation in order to assess the natural history of these patients
and to assess the predictive value of AV-Vel in these patients.
Methods
Patient population. All patients who were studied in our
utpatient clinic for valvular heart disease between 1995 and
009 and who were found to have a combination of at least
oderate AS with at least moderate AR were prospectively
ncluded into the study when they had preserved left
entricular function (ejection fraction 55%). Exclusion
riteria were additional hemodynamically significant valve
esions (moderate or severe) or the presence of symptoms.
According to these criteria, 71 consecutive patients (age
2  17 years; 21 women) were identified. At entry, 22
atients had moderate AS and moderate AR; 33 patients
ad moderate AR and severe AS; 7 patients had moderate
S and severe AR; and 9 patients had severe AR and severe
S. Thirty-five patients had bicuspid aortic valves, and 36
atients had tricuspid valves. All but 24 patients had moderate-
o-severe valve calcification, and 18 of those 24 patients had
icuspid aortic valves. Color Doppler showed additional mild
itral regurgitation in 32 patients and mild-to-moderate
itral regurgitation in 4. Sixteen patients had mild and 6 had
ild-to-moderate tricuspid regurgitation.
linical data. Clinical data were recorded at study entry as
ollows: age, sex, history of hypercholesterolemia (total
holesterol 200 mg/dl or patient under lipid-lowering
herapy), diabetes mellitus, arterial hypertension (on the
asis of the average of repeated measurements: blood
ressure 140/90 mm Hg for patients with nonsevere AR
nd systolic blood pressure 140 mm Hg for patients with
evere AR), and coronary artery disease (history of myocar-
ial infarction, angioplasty, coronary artery bypass grafting,
r angiographically documented coronary artery stenosis).
chocardiographic data. Echocardiography was per-
ormed using commercially available ultrasound systems. All
atients underwent a comprehensive examination including
-mode, 2-dimensional echocardiography, conventional
nd color Doppler by an experienced echocardiographer.
ultiple transducer positions were used to record AV-Vel
nd aortic valve area was calculated using the continuity
quation (16).
An integrated approach was used for the quantification of
Abbreviations
and Acronyms
AR  aortic regurgitation
AS  aortic stenosis
AV-Vel  peak aortic jet
velocity
CI  confidence intervalS and AR as proposed by current recommendations17–19). Severe AS was defined by an aortic valve area1.0
m2 and moderate AS by a valve area of 1.0 to 1.5 cm2. A
vena contracta of more than 6 mm (20) and a prominent
holodiastolic flow reversal in the descending aorta thoracalis
were used to define severe AR and moderate AR was
defined by a vena contracta of 3 to 6 mm. When assessing
the severity of AR, coexisting AS that is associated with left
ventricular hypertrophy and impaired relaxation may lead to
a prolonged pressure half-time. In the grading of lesion
severity, potential influences of the combined lesion on the
respective measures of severity were thus considered (3).
The presence of concomitant AR may lead to higher
transaortic flow rates and consequently to higher transval-
vular gradients.
The degree of aortic valve calcification was scored accord-
ing to previously described criteria (12).
Follow-up. Patients were followed prospectively after the
initial examination at the outpatient clinic for valvular heart
disease. Patients were scheduled to undergo follow-up
exams every 6 months based on a watchful waiting approach
and were referred to surgery once they had reached an
indication for surgery of either AR or AS (3,4). Before
undergoing surgery, coronary angiography was performed in
all patients. The follow-up information was obtained from
interviews with the patients, their relatives, and their phy-
sicians. Information regarding the development of cardiac
symptoms, eventual aortic valve replacement, and death was
obtained. Exercise testing was performed in selected pa-
tients when doubt about whether they were truly asymp-
tomatic existed. The decision to perform an exercise test was
made on an individual basis according to clinical judgment.
An exercise test was considered as an indication for surgery
when limiting dyspnea or angina occurred at subnormal
workload. Rapidly reversible breathlessness and fatigue at
workloads close to the age-sex predicted maximum work-
loads were not considered as an indication for surgery.
For the assessment of outcome, endpoints were defined as
cardiac death or indication for aortic valve replacement
according to the accepted indications for AR and AS in
agreement with current guidelines (5,6).
Deaths were classified as noncardiac or cardiac-based.
Cardiac deaths were classified as directly related to aortic
valve disease (sudden death, congestive heart failure) or to
other cardiac pathology. Patients who had a noncardiac
cause of death were censored at the time of death.
Statistical analysis. Quantitative baseline patient charac-
teristics are expressed as mean  SD. Event-free probabil-
ities and corresponding standard errors have been obtained
by the Kaplan-Meier method (Figs. 1 to 3). Follow-up was
quantified by means of the reverse Kaplan-Meier estimator
(21). The effect of different predictors (age, sex, hypercho-
lesterolemia, diabetes mellitus, arterial hypertension, coro-
nary artery disease, aortic valve area, and aortic valve jet
velocity) was studied by simple and multiple Cox regression
models. The strength of the effect was quantified by the
unadjusted and adjusted hazard ratio estimates. The as-
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April 9, 2013:1489–95 Combined Aortic Valve Diseasesumption of proportional hazards was assessed by adding
interactions of all prognostic factors with the log of time. A
p value 0.05 was considered to indicate statistical
ignificance.
For the graphical representation of the time-dependent
redictor (AV-Vel), the origin (time 0) for each of the
aplan-Meier curves (refers to Fig. 2A) signifies either
lassification at study entry or at the time of switching to a
igher AV-Vel group. Individuals changing to a higher
roup during follow-up are not censored in the initial group.
his permits an adequate graphical representation of the
agnitude of the effect of the time-dependent prognostic
actor (AV-Vel), which was analyzed as a time-dependent
ovariate in a standard Cox regression. Figure 2B represents
he outcome of patients stratified according to their last
ocumented AV-Vel: patients were censored in the lower
V-Vel group when their AV-Vel progressed and they
witched to a higher group.
esults
ollow-up information was complete for 70 patients
98.6%). The baseline patient characteristics are summa-
ized in Table 1.
chocardiographic characteristics. Pressure half-time was
ignificantly shorter in patients with severe AR than in those
ith moderate AR (293  25 ms vs. 388  15 ms; p 
.0021). Furthermore, left ventricular end-diastolic diame-
ers were significantly larger in patients with severe AR as
ompared to patients with moderate AR (61.4 1.7 mm vs.
3.1  0.8 mm; p  0.001). At baseline, 36 patients
resented with an AV-Vel of 3.0 to 3.9 m/s, 28 patients
Figure 1 Event-Free Survival for Patients
With Combined Aortic Valve Disease
Kaplan-Meier event-free survival for the entire patient population with combined
stenotic and regurgitant aortic valve disease. Pts  patients.ith an AV-Vel of 4.0 to 4.9 m/s, and 7 patients with anV-Vel of 5.0 m/s. During follow-up, 26 patients had a
rogression of their AV-Vel from 3.0 to 3.9 m/s to 4.0 to
.9 m/s, 23 patients from 4.0 to 4.9 m/s to 5m/s (11 of
hese had already progressed from 3.0 to 3.9 m/s to 4.0 to
.9 m/s) and 3 patients progressed from 3.0 to 3.9 m/s to
5.0 m/s.
vent-free survival. During a median potential follow-up
f 8.9 years, 50 patients developed criteria warranting aortic
alve replacement. No cardiac deaths occurred in asymp-
omatic patients without an indication for surgery. Event-
Figure 2 Event-Free Survival Stratified
by Peak Aortic Jet Velocity
(A) Kaplan-Meier event-free survival for patients with combined stenotic and
regurgitant aortic valve disease. Individuals changing to a higher group during
follow-up are not censored in the initial group. This permits an adequate graph-
ical representation of the magnitude of the effect of the time-dependent prog-
nostic factor (peak aortic jet velocity [AV-Vel]); p  0.0001 (derived from
univariate Cox regression, see Table 2). (B) Kaplan-Meier event-free survival
curves representing the outcome of patients stratified according to their last
documented AV-Vel. Patients were censored in the lower AV-Vel group when
their AV-Vel progressed and they switched to a higher group.
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Combined Aortic Valve Disease April 9, 2013:1489–95free survival was 82  5%, 62  6%, 49  6%, 33  6%,
and 19  5% at 1, 2, 3, 4, and 6 years, respectively (Fig. 1).
Deaths. One noncardiac death occurred in a patient who
did not develop criteria for surgery. This patient died of late
sequelae after a major stroke with hemiparesis and severe
disability. Three patients had an indication for surgery due
to progressive symptoms but refused aortic valve replace-
ment surgery. Of these, 1 patient died of congestive heart
failure, 1 of a stroke, and the cause of death remained
unknown in 1 patient. No sudden deaths occurred during
follow-up, and 1 patient died 10 days after aortic valve
replacement.
Indications for aortic valve replacement surgery. During
follow-up, surgery was indicated in 50 patients. When
reaching an indication for surgery, AS was the predominant
lesion in 28 patients; AR was the predominant lesion in 8
patients; and both regurgitation and stenosis were severe in
14 patients. Indications for surgery were as follows: symp-
toms (n  33); symptoms unmasked by an exercise test
(n  3); rapid hemodynamic progression of AS, defined by
an increase in AV-Vel of at least 0.3 m/s within 1 year in the
presence of a calcified aortic valve (n  5); aortic aneurysm
n  3; of which 2 had bicuspid aortic valves); aortic
issection in a patient with a tricuspid aortic valve (n  1);
efore major noncardiac surgery (n  2); endocarditis (n 
); and left ventricular dysfunction (n  1). No patient
equired surgery because of criteria of left ventricular
ilation.
urgery. Forty-three of these patients underwent aortic
Figure 3 Event-Free Survival Stratified by Severity
of Aortic Stenosis and Aortic Regurgitation
Kaplan-Meier event-free survival for patients with a combination of moderate
aortic stenosis and moderate aortic regurgitation (red line), severe aortic ste-
nosis and moderate aortic regurgitation (green line), moderate aortic stenosis
and severe aortic regurgitation (blue line), and severe aortic stenosis and
severe aortic regurgitation (orange line).alve replacement, whereas 6 patients refused surgery. Oneatient was denied surgery because of metastatic colorectal
ancer from which he died after 1 year. Fifteen patients
eceived a biological valve prosthesis, 17 a mechanical valve
rosthesis, and 10 underwent a Ross procedure. One patient
eceived concomitant aortocoronary bypass surgery.
ost-operative survival. One death occurred in a 67-year-
ld man 10 days after aortic valve replacement and single
oronary artery bypass surgery. This patient had presented
ith mild exertional dyspnea and a pre-operative AV-Vel of
.7 m/s. No post-operative deaths were observed during
ollow-up.
otential prognostic factors. Among patients with com-
ined aortic valve disease, patients with moderate and those
ith severe AS at baseline did not have significantly
ifferent event-free survival rates: patients with an aortic
alve area of 1.0 cm2 had an outcome that was comparable
to those with a valve area between 1.0 and 1.5 cm2 (p  0.57).
lso the degree of AR did not have prognostic value and
atients with moderate AR and those with severe AR had a
imilar outcome (p  0.81).
Patients with moderate AS and moderate AR had event-
ree survival rates of 100  0%, 75  10%, 24  10%, and
8  9% at 1, 2, 4, and 6 years, respectively, as compared to
7 8%, 53 9%, 42 9%, and 19 8% for patients with
severe AS and moderate AR; 71  17%, 54  20%, 36 
20%, and 18  16% for patients with moderate AS and
severe AR and 76  15%, 63  17%, 42  21%, and 21 
8% for patients with severe AS and severe AR (p  0.9)
(Fig. 3). However, AV-Vel was a significant predictor of
outcome allowing further risk stratification among patients
with combined stenotic and regurgitant aortic valve disease.
The likelihood of having an event with an AV-Vel between
3.0 and 3.9 m/s is low (Fig. 2B), however rapid progression
to a higher velocity group with the subsequent occurrence of
events is common in these patients (Fig. 2A).
Event-free survival rates for patients with an AV-Vel
between 3.0 and 3.9 m/s were 94 4%, 88 6%, 65 9%,
and 51  9% after 1, 2, 4, and 6 years, respectively.
vent-free survival rates were significantly worse for pa-
Baseline Patient Characteristics (N  71)Table 1 Baseline Patient Characteristics (N  71)
Female 21 (30)
Age, yrs 52 17
Pressure half-time, ms 361 102
Peak aortic jet velocity, m/s 4.31 0.61
Aortic mean gradient, mm Hg 45.9 15.4
Aortic valve area, cm2 0.98 0.25
Indexed aortic valve area, cm2/m2 0.50 0.16
Left ventricular diameter, mm 54 4.9
Interventricular septum, mm 13.5 2.9
Bicuspid aortic valve 35 (49)
Coronary artery disease 8 (11)
Hypertension 31 (44)
Diabetes mellitus 10 (14)
Hypercholesterolemia 22 (31)Values are n (%) or mean  SD.
a4
6
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April 9, 2013:1489–95 Combined Aortic Valve Diseasetients with an AV-Vel between 4.0 and 4.9 m/s: 92  4%
t 1 year; 67  7% at 2 years; 38  8% at 4 years; and 12 
6% at 6 years. Event-free survival rates were even worse for
patients with an AV-Vel5.0 m/s: 67 8% at 1 year; 39
10% at 2 years; 17  9% at 4 years; and 0% at 6 years
(p  0.001) (Fig. 2A).
Event-free survival rates for patients with coronary artery
disease were 63  17%, 25  15%, and 0  0% after 1, 2,
, and 6 years, respectively, as compared with 85  5%,
9  6%, 36  7%, and 22  6% after 1, 2, 4, and 6 years,
respectively, for patients where no coronary artery disease
was documented upon cardiac catheterization (p 0.0019).
In univariate analysis, age and arterial hypertension were
significant predictors of outcome (p  0.005 and p  0.0003,
respectively).
In the multivariate analysis (Table 2), AV-Vel and
coronary artery disease were the only significant predictors
of outcome. The hazard ratio for an increase of AV-Vel
from 3.0 to 3.9m/s to 4.0 to 4.9 m/s or from 4.0 to 4.9 m/s
to 5.0 m/s was 3.3 (95% confidence interval [CI]: 2.1 to
5.3). Age, sex, hypercholesterolemia, diabetes mellitus, and
arterial hypertension were not found to be significant
predictors of outcome in the multivariate analysis. A time-
dependent effect of aortic valve area was detected as an
interaction of aortic valve area with the log of time.
However, this effect was not further explored by weighted
Cox regression due to imprecision in the determination of
aortic valve area related to technical limitations of the
continuity equation and the lack of clinical relevance and
plausibility of such a potential effect in daily clinical practice.
The effect of all other considered factors appeared constant
in time.
Discussion
Disease etiology. The main disease etiologies were bicus-
pid and degenerative calcific aortic valve disease, accounting
for approximately one-half of the patients, each. Obviously
it cannot be excluded that some of the extensively calcified
valves have an underlying masked bicuspid etiology (22). In
an analysis of surgical findings in patients who had under-
Event-Free Survival: Univariate and Multivariate Aof Potential Cl nical and Echocardiographic PrTable 2 E ent-Free Survival: Univariate nd Mof Potential Clinical and Echocard
Variable
Univariate An
HR (95% CI)
Peak aortic jet velocity* 3.38 (2.19–5.22)
Aortic valve area† 0.85 (0.48–1.50)
Age‡ 1.41 (1.16–1.71)
Sex 0.77 (0.41–1.47)
Hypertension 2.54 (1.38–4.67)
Hypercholesterolemia 1.43 (0.77–2.65)
Diabetes 1.58 (0.70–3.53)
Coronary artery disease 4.91 (2.07–11.67)
*Hazard ratios refer to an increase of peak aortic jet velocity from 3 to
2a comparison of aortic valve area 1.0 cm and a valve area between 1.0 a
CI  confidence interval; HR  hazard ratio.gone aortic valve surgery for combined aortic valve disease in
the 1960s and 1970s, post-inflammatory disease accounted
for 69% of the cases of combined aortic valve disease (23).
The fact that no patient in this series had rheumatic disease
can be explained by its decreasing incidence and the fact that
these patients frequently present with concomitant mitral
disease, which was an exclusion criterion in the present
study. Six percent (n  4) of the patients required surgery
because of aortic aneurysm or dissection, of which one-half
had a bicuspid aortic valve. The ascending aorta should thus
be routinely assessed during the follow-up visits.
Natural history of combined aortic valve disease. This is
the first study to specifically assess the natural history and
the outcome of a relatively large group of patients with
combined stenotic and regurgitant aortic valve disease. Most
available evidence on the natural history of aortic valve
disease is related to either AS or AR. Due to a strict lack of
data for combined aortic valve disease, no specific recom-
mendations have been issued so far for combined stenotic
and regurgitant aortic valve disease. Although a substantial
number of the patients included in the present study had
only moderate combined aortic valve disease and although
they were relatively young, with a mean age of 51 years, the
overall event rate was high: 38% of the patients required
surgery within 2 years and 67% within 4 years. Thus, close
clinical and echocardiographic follow-up is recommended
in this patient group, even when a patient presents with
combined aortic valve disease of only moderate severity.
Patients should also be educated about the likelihood of a
rapid onset of symptoms and that aortic valve surgery may
be required in the near future.
Indications for surgery. The current indications for sur-
gery as well as recommendations on the scheduling of
follow-up intervals have been defined for single-valve dis-
ease and are “extrapolated” to patients with combined valve
disease.
Although many clinicians follow these patients conserva-
tively until surgical criteria defined for AS, AR, or the aorta
are reached, the present data confirm for the first time that
such a strategy is safe and results in good surgical and
isorsariate Analysis
phic Predictors
Multivariate Analysis
p Value HR (95% CI) p Value
0.0001 3.32 (2.06–5.34) 0.0001
0.50 0.65 (0.33–1.28) 0.21
0.005 1.14 (0.89–1.45) 0.30
0.43 0.68 (0.32–1.46) 0.33
0.0026 1.37 (0.61–3.07) 0.44
0.26 0.64 (0.30–1.34) 0.23
0.27 1.34 (0.50–3.62) 0.56
0.0003 4.01 (1.38–11.66) 0.01
to 4 to 5 m/s or from 4 to 5 m/s to 5 m/s. †Hazard ratios refer to
2nalysedictu tiv
iogra
alysis
4 m/s
nd 1.5 cm . ‡Hazard ratios refer to an increase of age by 10 years.
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Combined Aortic Valve Disease April 9, 2013:1489–95post-operative outcomes. One cardiac death occurred 10
days after the procedure in the only patient in our series that
had undergone concomitant aortocoronary bypass surgery.
At the same time, patients can expect to have a good
outcome when surgery is performed at that stage. Coronary
artery disease, which was relatively rare in this younger
patient population with a prevalence of 11%, was a signif-
icant predictor of outcome in multivariate analysis. Com-
bined aortic valve disease seems to be less well tolerated in
the presence of coronary artery disease, which leads to a
relatively early symptom onset.
Peak aortic jet velocity as a measure of severity of
combined aortic valve disease. The precise quantification
of the severity of each component of combined aortic valve
disease is complex because the measures of severity may be
influenced by the coexisting lesion (3). As has already been
mentioned, AR may lead to higher transvalvular gradients
related to an increased transaortic flow rate, and pressure
half-time may be prolonged when left ventricular hypertro-
phy with impaired relaxation is present due to AS (24).
AV-Vel has the potential advantage of being a simple,
reproducible, and quantitative measure that comprehen-
sively assesses the overall hemodynamic load of combined
aortic valve disease. In contrast, event-free survival was
comparable for the 4 patient subgroups that were stratified
according to semiquantitative severity of AS and AR. Even
patients having moderate stenosis and moderate regurgita-
tion had a high event rate. The present study demonstrates
that AV-Vel is a solid parameter that allows the prediction
of event-free survival in patients with combined aortic valve
disease. Its value is thus also of importance, when schedul-
ing control exams in these patients and should be integrated
into the discussion of the timing of surgery.
Moreover, no additional prognostic information is pro-
vided by aortic valve area. This may not be surprising,
because aortic valve area reflects the severity of AS only,
without accounting for AR severity.
We have previously shown that AV-Vel predicts outcome
in isolated AS across the entire spectrum from mild to very
severe disease (14,15). Patients with combined aortic disease
with an AV-Vel of 3.0 to 3.9 m/s have lower event-free
survival rates (65  9% at 2 years and 51  9% at 4 years)
than do patients with isolated moderate AS (AV-Vel 3.0 to
3.9 m/s) with an event-free survival of 79  4% and 61 
% at 2 and 4 years, respectively (14).
For an AV-Vel of 4.0 to 4.9 m/s and an AV-Vel 5.0
/s, event rates are comparable for patients with combined
ortic disease and those with isolated AS. For patients with
n AV-Vel of 4.0 to 4.9 m/s, event-free survival rates at 2
nd 4 years are 67  7% and 38  8% when they have
ombined aortic disease as compared to 70  5% and 39 
6% for patients with isolated AS, respectively. For patients
ith an AV-Vel5.0 m/s, event-free survival rates at 2 and
years are 39  10% and 17  9% when they have
ombined aortic disease as compared to 36  5% and 12 
% for patients with isolated AS, respectively (15).tudy limitations. Regurgitant orifice area and regurgitant
olume measures were not systematically used in the present
tudy; however, a careful integrated approach for the assess-
ent of AR was performed as recommended (17,18). The
tudy was not designed to assess and compare surgical risks
nd is limited in this regard by the number of patients
ndergoing surgery.
onclusions
symptomatic patients with combined aortic valve disease
an be safely followed until surgical criteria defined for AS,
R, or the aorta are reached. Good surgical and post-
perative outcomes are achieved when following such a
trategy. However, high event rates can be expected despite
relatively young age of the population and even in patients
ith moderate disease severity. AV-Vel, which reflects both
tenosis and regurgitant severity, provides an objective and
asily assessable parameter to risk stratify these patients.
Reprint requests and correspondence: Dr. Raphael Rosenhek,
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